Xcelom Limited (Global)
About Us
Xcelom Limited: Pioneering Genomic Excellence in Hong Kong & Beyond
Founded in 2014 by Professor Dennis Lo Yuk Ming and his team, Xcelom has established itself as Hong Kong’s largest NIPT provider, operating an ISO 15189 and CAP-accredited facility backed by CUHK patent licenses.
Since becoming a wholly-owned subsidiary of Berry Genomics in 2017, we have leveraged the resources of a global leader—China’s second-largest NIPT provider and a pioneer in clinical long-read sequencing (LRS). Now acting as the international hub for Berry Genomics and the authorized distributor for Haorui Genomics, Xcelom empowers healthcare providers, laboratories, and organizations worldwide with reliable, cutting-edge clinical sequencing solutions.
Xcelom is the authorized sole representative of Berry Genomics for overseas business operations and the authorized distributor for Haorui Genomics laboratory solutions.
The Risk is NOT Knowing
Mission
Deliver innovative genomic services to our community
Vision
Pioneer the genomic service industry
Philosophy
Genome decoding makes impossible early detection possible
Global Business
Our portfolio covers sequencing-based screening and molecular diagnostics, including prenatal testing, carrier screening, and rare disease applications. We offer send-out testing, co-develop assays, and provide scalable end-to-end technology transfer so services can be run in-house. Deliverables include assay development, reagents, technical support and training, and bioinformatics + LIMS software, supported by strong R&D capabilities and proven operational experience.
Business Profilo
Authorized distributor of Berry Genomics & Haorui Genomics solution
End-to-End Clinical Solution
Backed by our operational experience and ISO certified manufacturing bases in Hangzhou and Fuzhou
Send-out Testing
With our affiliated labs accredited to ISO 13485, ISO 15189, CAP and others
Co-develop Customized Service
Supported by our strong R&D capabilities
Distributing Excellence: Our Partners
Founded in May 2010 and listed on the A-share market in 2017 (Stock Code: 000710), Berry Genomics is a premier genetic biotech company to delivering advanced genomic solutions. Driven by independent R&D, they are dedicated to translating genetic testing technologies into practical clinical applications. Their portfolio empowers clinical laboratories with cutting-edge products, including LRS panels, CNV-seq, NIPT, and WES, covering critical areas such as reproductive health and disease screening.
Headquartered in Beijing, Berry Genomics operates an extensive network of medical laboratories and manufacturing bases for reagents and equipment. This robust infrastructure allows them to provide comprehensive genetic testing solutions to over 6,000 medical institutions, research centers, and universities. We are proud to bring these industry-leading diagnostic tools to global market.
Founded in 2019, Haorui Genomics is a pioneering company specializing in the application of LRS technology for clinical transplantation and transfusion medicine. They developed proprietary molecular solutions for high-resolution HLA genotyping and blood group typing (including ABO and Rh). As their distributor, we are excited to offer these advanced LRS capabilities to enhance compatibility testing and transplant outcomes.